JP2024540319A5 - - Google Patents
Info
- Publication number
- JP2024540319A5 JP2024540319A5 JP2024526661A JP2024526661A JP2024540319A5 JP 2024540319 A5 JP2024540319 A5 JP 2024540319A5 JP 2024526661 A JP2024526661 A JP 2024526661A JP 2024526661 A JP2024526661 A JP 2024526661A JP 2024540319 A5 JP2024540319 A5 JP 2024540319A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cftr
- betamethasone
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306554.3 | 2021-11-05 | ||
| EP21306554 | 2021-11-05 | ||
| PCT/EP2022/080807 WO2023079072A1 (en) | 2021-11-05 | 2022-11-04 | Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540319A JP2024540319A (ja) | 2024-10-31 |
| JP2024540319A5 true JP2024540319A5 (cg-RX-API-DMAC10.html) | 2025-09-16 |
Family
ID=78770564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526661A Pending JP2024540319A (ja) | 2021-11-05 | 2022-11-04 | 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20260158056A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4426317A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024540319A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023079072A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026502695A (ja) * | 2023-01-26 | 2026-01-23 | インシグニア・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー | 変形性関節症の処置のための医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060691B2 (en) * | 2002-10-10 | 2006-06-13 | Giuseppe Petrigni | Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases |
| FR2847818B1 (fr) | 2002-11-28 | 2008-04-04 | Agro Ind Rech S Et Dev Ard | Composition pharmaceutique a base d'acide hyaluronique |
| FR2919185B1 (fr) | 2007-07-23 | 2010-09-10 | Ard Sa | Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses |
| CN116515924A (zh) * | 2014-04-16 | 2023-08-01 | 青岛惠诺德生物科技有限公司 | 一种生物活性透明质酸片段、其生产方法、应用、制剂及含有该制剂的物品 |
| US20230172950A1 (en) * | 2020-04-29 | 2023-06-08 | Avm Biotechnology, Llc | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus |
| CN111632042B (zh) * | 2020-06-15 | 2022-08-26 | 华熙生物科技股份有限公司 | 透明质酸吸入剂及其制备方法和应用 |
| WO2022236585A1 (zh) * | 2021-05-10 | 2022-11-17 | 傅毓秀 | 玻尿酸用于制备治疗肺纤维化药剂的用途 |
-
2022
- 2022-11-04 EP EP22813961.4A patent/EP4426317A1/en active Pending
- 2022-11-04 JP JP2024526661A patent/JP2024540319A/ja active Pending
- 2022-11-04 WO PCT/EP2022/080807 patent/WO2023079072A1/en not_active Ceased
- 2022-11-04 US US18/706,622 patent/US20260158056A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Edsbäcker et al. | Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? | |
| US5192528A (en) | Corticosteroid inhalation treatment method | |
| Toogood | High-dose inhaled steroid therapy for asthma | |
| JP2017197569A5 (cg-RX-API-DMAC10.html) | ||
| Saha et al. | Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids | |
| JP2015506983A5 (cg-RX-API-DMAC10.html) | ||
| JP2022507103A5 (cg-RX-API-DMAC10.html) | ||
| Vance et al. | Effects of particle size of inhaled corticosteroid on the voice | |
| De Wachter et al. | Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide | |
| Hatton et al. | A comparison of ‘abruptly stopping’with ‘tailing off’oral corticosteroids in acute asthma | |
| JP2020536859A5 (cg-RX-API-DMAC10.html) | ||
| Szefler | A review of budesonide inhalation suspension in the treatment of pediatric asthma | |
| JP2022500364A5 (cg-RX-API-DMAC10.html) | ||
| Ververeli et al. | Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma | |
| EP4426317A1 (en) | Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation | |
| Hubbard et al. | Inhaled corticosteroids, bone mineral density and fracture in older people | |
| JP2002512193A (ja) | 軽度／初期型のｃｏｐｄ（慢性閉塞性肺疾患）を処置することを目的とした薬物の製造のための糖質副腎皮質ステロイドの使用 | |
| Bateman et al. | Randomized comparison of ciclesonide 160 and 640 μg/day in severe asthma | |
| Lipworth et al. | High-dose inhaled steroids in asthmatic children | |
| König | Evidence for benefits of early intervention with non‐steroidal drugs in asthma | |
| Smith et al. | A controlled trial of beclomethasone dipropionate for asthma | |
| JP2024513388A5 (cg-RX-API-DMAC10.html) | ||
| Escribano et al. | Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial | |
| Szefler et al. | Role of budesonide as maintenance therapy for children with asthma | |
| Mathew et al. | INHALED CORTICOSTEROIDS: AN OVERLOOKED CAUSE OF ADRENAL INSUFFICIENCY |